Awaiting development: Guidance and quality standards

Showing 141 to 150 of 332

Guidance and quality standards awaiting development
Title	Type
Gout	Quality standard
Heart valve disease in adults	Quality standard
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]	Technology appraisal guidance
Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]	Technology appraisal guidance
Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]	Technology appraisal guidance
Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]	Technology appraisal guidance
Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579]	Technology appraisal guidance
Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor [TSID8376]	Technology appraisal guidance
In-situ Normothermic Regional Perfusion system for DCD donors - liver	Interventional procedures guidance
Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]	Technology appraisal guidance